SG11201500912XA - Niclosamide and its derivatives for use in the treatment of solid tumors - Google Patents
Niclosamide and its derivatives for use in the treatment of solid tumorsInfo
- Publication number
- SG11201500912XA SG11201500912XA SG11201500912XA SG11201500912XA SG11201500912XA SG 11201500912X A SG11201500912X A SG 11201500912XA SG 11201500912X A SG11201500912X A SG 11201500912XA SG 11201500912X A SG11201500912X A SG 11201500912XA SG 11201500912X A SG11201500912X A SG 11201500912XA
- Authority
- SG
- Singapore
- Prior art keywords
- niclosamide
- derivatives
- treatment
- solid tumors
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/065364 WO2014023329A1 (en) | 2012-08-06 | 2012-08-06 | Niclosamide and its derivatives for use in the treatment of solid tumors |
PCT/EP2013/066484 WO2014023732A1 (en) | 2012-08-06 | 2013-08-06 | Niclosamide and its derivatives for use in the treatment of solid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201500912XA true SG11201500912XA (en) | 2015-04-29 |
Family
ID=48917552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500912XA SG11201500912XA (en) | 2012-08-06 | 2013-08-06 | Niclosamide and its derivatives for use in the treatment of solid tumors |
Country Status (15)
Country | Link |
---|---|
US (1) | US9844522B2 (pt) |
EP (1) | EP2879671A1 (pt) |
JP (1) | JP6272861B2 (pt) |
CN (1) | CN104936586A (pt) |
AU (1) | AU2013301542A1 (pt) |
BR (1) | BR112015002706A8 (pt) |
CA (1) | CA2880916A1 (pt) |
CL (1) | CL2015000289A1 (pt) |
IL (1) | IL237125A0 (pt) |
MX (1) | MX2015001716A (pt) |
PE (1) | PE20150764A1 (pt) |
PH (1) | PH12015500252A1 (pt) |
RU (1) | RU2015107753A (pt) |
SG (1) | SG11201500912XA (pt) |
WO (2) | WO2014023329A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2986930C (en) | 2015-06-24 | 2023-09-26 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
MX2018002586A (es) | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala. |
CN108883084A (zh) * | 2015-09-16 | 2018-11-23 | 新加坡科技研究局 | 氯硝柳胺在p53缺失细胞的处理中的应用 |
WO2017123809A1 (en) | 2016-01-12 | 2017-07-20 | Taipei Medical University | Compounds for inhibiting cancer and virus |
US20170209616A1 (en) * | 2016-01-26 | 2017-07-27 | The Procter & Gamble Company | Absorbent cores with high molecular weight superabsorbent immobilizer |
CN105687171A (zh) * | 2016-01-28 | 2016-06-22 | 昆明医科大学 | 一种阿米诺喹的新用途 |
TWI631944B (zh) | 2016-10-14 | 2018-08-11 | 長庚大學 | 氯硝柳胺及其衍生物的用途 |
US20210041443A1 (en) * | 2018-04-24 | 2021-02-11 | Universidade Do Minho | Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof |
US11987579B2 (en) | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
WO2021142238A1 (en) * | 2020-01-10 | 2021-07-15 | First Wave Bio, Inc. | Deuterated niclosamide |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2022124525A1 (ko) * | 2020-12-08 | 2022-06-16 | 주식회사 대웅제약 | 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물 |
CN114601833A (zh) * | 2022-04-02 | 2022-06-10 | 北京大学口腔医学院 | 一种治疗肿瘤的化学药物组合 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
AU2002222853A1 (en) * | 2000-12-07 | 2002-06-18 | Astrazeneca Ab | Therapeutic compounds |
WO2003053926A1 (fr) | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Nouveau derive de phenylalanine |
CA2483915A1 (en) | 2002-05-02 | 2003-11-13 | University Of Rochester | Vectors having both isoforms of b-hexosaminidase |
AU2003249244A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
US20050250709A1 (en) * | 2003-12-19 | 2005-11-10 | Bionaut Pharmaceuticals | Anti-neoplastic agents, combination therapies and related methods |
US20060009506A1 (en) * | 2004-07-09 | 2006-01-12 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
US8163744B2 (en) * | 2005-03-18 | 2012-04-24 | Nexuspharma, Inc. | Tetrahydro-isoquinolin-1-ones for the treatment of cancer |
TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
US20130023498A1 (en) * | 2008-02-20 | 2013-01-24 | The Wistar Institute and North Carolina State University | MicroRNA Modulators and Method for Identifying and Using the Same |
US8835506B2 (en) * | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
EP2373343B1 (en) * | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
CN103764659A (zh) * | 2011-06-15 | 2014-04-30 | 生命与大脑有限公司 | 抑制胶质母细胞瘤的化合物及其用途 |
WO2013049045A1 (en) * | 2011-09-27 | 2013-04-04 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
-
2012
- 2012-08-06 WO PCT/EP2012/065364 patent/WO2014023329A1/en active Application Filing
-
2013
- 2013-08-06 SG SG11201500912XA patent/SG11201500912XA/en unknown
- 2013-08-06 AU AU2013301542A patent/AU2013301542A1/en not_active Abandoned
- 2013-08-06 US US14/420,164 patent/US9844522B2/en not_active Expired - Fee Related
- 2013-08-06 WO PCT/EP2013/066484 patent/WO2014023732A1/en active Application Filing
- 2013-08-06 BR BR112015002706A patent/BR112015002706A8/pt not_active IP Right Cessation
- 2013-08-06 MX MX2015001716A patent/MX2015001716A/es unknown
- 2013-08-06 PE PE2015000153A patent/PE20150764A1/es not_active Application Discontinuation
- 2013-08-06 CA CA2880916A patent/CA2880916A1/en not_active Abandoned
- 2013-08-06 RU RU2015107753A patent/RU2015107753A/ru not_active Application Discontinuation
- 2013-08-06 JP JP2015525864A patent/JP6272861B2/ja not_active Expired - Fee Related
- 2013-08-06 CN CN201380046667.9A patent/CN104936586A/zh active Pending
- 2013-08-06 EP EP13745422.9A patent/EP2879671A1/en not_active Withdrawn
-
2015
- 2015-02-05 PH PH12015500252A patent/PH12015500252A1/en unknown
- 2015-02-05 IL IL237125A patent/IL237125A0/en unknown
- 2015-02-06 CL CL2015000289A patent/CL2015000289A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20150764A1 (es) | 2015-06-04 |
JP2015528437A (ja) | 2015-09-28 |
WO2014023732A1 (en) | 2014-02-13 |
EP2879671A1 (en) | 2015-06-10 |
BR112015002706A8 (pt) | 2017-10-10 |
CN104936586A (zh) | 2015-09-23 |
CL2015000289A1 (es) | 2015-06-12 |
RU2015107753A (ru) | 2016-09-27 |
CA2880916A1 (en) | 2014-02-13 |
IL237125A0 (en) | 2015-03-31 |
PH12015500252A1 (en) | 2015-03-30 |
MX2015001716A (es) | 2015-12-08 |
US20150174086A1 (en) | 2015-06-25 |
AU2013301542A1 (en) | 2015-02-19 |
WO2014023329A1 (en) | 2014-02-13 |
JP6272861B2 (ja) | 2018-01-31 |
US9844522B2 (en) | 2017-12-19 |
BR112015002706A2 (pt) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
HUE049129T2 (hu) | Piridopirazin és naftiridin-származékok rák kezelésére | |
PL3004108T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3- | |
HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
HRP20181879T1 (hr) | Spojevi za liječenje pretilosti i postupci za njihovu upotrebu | |
HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use gpbp-1 | |
IL233875A (en) | Preparation and use for the treatment of anal fissures | |
SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis |